We study the capital structure changes of drug firms after an investment ]opportunity shock brought about by the Biologics Price Competition and Innovation Act. Using a difference ]in ]difference approach, we show that the shock led drug firms to make their capital structures less constraining by decreasing leverage, shortening debt maturity, increasing unsecured debt, and reducing convertible debt. New debt covenants became less restrictive and firms raised equity to preserve borrowing capacity. Our results support the view that firms actively manage their capital structures to bolster financial flexibility and increase debt capacity in response to new investment opportunities.
ASJC Scopus subject areas
- Economics and Econometrics